Your thyroid gland secretes mostly T4 (thyroxine), an inactive prohormone that must be converted to T3 (triiodothyronine) to exert biological effects. This conversion happens locally in tissues¹¹ This conversion happens locally in tissues
The brain derives up to 80% of its intracellular T3 from circulating T4 through local conversion via the type 2 deiodinase (DIO2) enzyme. The Thr92Ala variant changes a threonine to alanine at position 92 of the DIO2 protein, altering enzyme efficiency²² altering enzyme efficiency
Castagna et al. J Clin Endocrinol Metab 2017 and altering its cellular behavior. This common variant affects roughly 36% of people of European ancestry³³ roughly 36% of people of European ancestry
Present in 11-16% as CC homozygotes and has become a focal point in debates about optimal thyroid hormone replacement therapy.

The Mechanism

The wild-type Thr92 version of DIO2 normally resides in the endoplasmic reticulum, where it efficiently converts T4 to T3. The Ala92 variant protein has altered cellular behavior⁴⁴ The Ala92 variant protein has altered cellular behavior
Studies suggest reduced enzyme efficiency and altered protein dynamics, which disrupts normal T4-to-T3 conversion. Comarella et al. found C-allele carriers had lower post-treatment weight variation in Graves' disease⁵⁵ Comarella et al. found C-allele carriers had lower post-treatment weight variation in Graves' disease
Suggesting impaired metabolic adaptation linked to reduced DIO2 activity, and the effect is most significant in tissues that rely heavily on local T3 production like the brain and pituitary gland. Because DIO2 activity in the hypothalamus and pituitary regulates TSH secretion through negative feedback, the variant can create a mismatch: normal serum TSH and T4 levels may mask inadequate tissue-level T3, especially in the central nervous system.

The Evidence

The landmark study establishing clinical relevance of this variant is a pharmacogenetic analysis of 552 hypothyroid patients from the WATTS randomized trial⁶⁶ 552 hypothyroid patients from the WATTS randomized trial
Panicker et al. J Clin Endocrinol Metab 2009. The CC genotype was present in 16% of participants and was associated with worse baseline psychological well-being scores⁷⁷ worse baseline psychological well-being scores
14.1 vs 12.8 on GHQ-12, P=0.03 compared to TT carriers. More importantly, CC carriers showed greater improvement on T4+T3 combination therapy⁸⁸ greater improvement on T4+T3 combination therapy
2.3 GHQ points at 3 months, P=0.03 compared to T4 alone, despite no differences in serum thyroid hormone levels between genotypes.

A Danish randomized controlled trial of 45 hypothyroid patients⁹⁹ Danish randomized controlled trial of 45 hypothyroid patients
Carle et al. Eur Thyroid J 2017 found that preference for T4+T3 combination therapy increased in a dose-dependent manner with genetic burden: 42% preferred combination therapy with no polymorphisms, 63% with one polymorphism (DIO2 or MCT10), and 100% with both¹⁰¹⁰ 42% preferred combination therapy with no polymorphisms, 63% with one polymorphism (DIO2 or MCT10), and 100% with both
p=0.009 for trend. This suggests the DIO2 variant has a measurable, though incomplete, effect on treatment satisfaction.

In thyroidectomized patients on levothyroxine replacement¹¹¹¹ thyroidectomized patients on levothyroxine replacement
Castagna et al. J Clin Endocrinol Metab 2017, carriers of the Thr92Ala variant showed significantly lower mean serum free T3 levels¹²¹² significantly lower mean serum free T3 levels
FT3 was lower in carriers of the mutated allele(s) vs wild-type, despite similar TSH compared to wild-type patients, providing biochemical confirmation that the variant impairs systemic T4-to-T3 conversion. However, not all studies show associations: [a Dutch population study of over 1,000 individuals | Wouters et al. Thyroid 2017] found no association with thyroid hormone levels or quality of life in the general population, suggesting the variant's effects may be most apparent in patients who lack endogenous thyroid function.

Beyond thyroid therapy, the variant has been linked to higher body mass index and altered metabolic regulation in some populations, though findings are inconsistent. Associations have also been reported with osteoarthritis, bipolar disorder, and schizophrenia¹³¹³ osteoarthritis, bipolar disorder, and schizophrenia
DIO2 is expressed in growth plate cartilage and multiple brain regions.

Practical Implications

If you're on levothyroxine (T4) monotherapy and still experience fatigue, weight gain, brain fog, or mood disturbances¹⁴¹⁴ fatigue, weight gain, brain fog, or mood disturbances
Common persistent symptoms in euthyroid patients despite normal TSH levels, the Thr92Ala variant could be contributing. The evidence supports considering T4+T3 combination therapy for C-allele carriers who remain symptomatic. Current guidelines suggest an L-T4/L-T3 dose ratio between 13:1 and 20:1 by weight¹⁵¹⁵ an L-T4/L-T3 dose ratio between 13:1 and 20:1 by weight
European Thyroid Association 2012 guidelines, with T3 typically split into two daily doses due to its shorter half-life.

Testing for this variant can be useful before thyroidectomy to anticipate which patients may struggle with T4 monotherapy. However, genetic testing is not widely available through standard medical channels; historically, 23andMe included rs225014 on their v3 and v4 chips, but it was removed from the v5 chip¹⁶¹⁶ it was removed from the v5 chip
No longer genotyped as of 2017. Specialized laboratories like Regenerus Labs offer targeted DIO2 genotyping.

For those with hypothyroidism who are not on thyroid medication, ensuring adequate selenium and iodine intake¹⁷¹⁷ selenium and iodine intake
DIO2 is a selenoprotein requiring selenium for function supports whatever DIO2 enzyme activity remains. However, dietary interventions alone are unlikely to fully compensate for reduced enzyme efficiency in homozygous C-allele carriers.

Interactions

The DIO2 variant interacts with rs17606253 in the MCT10 gene, which encodes a thyroid hormone transporter. The Danish RCT showed that patients with both polymorphisms had 100% preference for T4+T3 combination therapy¹⁸¹⁸ The Danish RCT showed that patients with both polymorphisms had 100% preference for T4+T3 combination therapy
Carle et al. 2017, suggesting the combination creates a more severe impairment in cellular thyroid hormone availability than either variant alone. This makes biological sense: MCT10 transports thyroid hormones into cells, and DIO2 converts T4 to T3 once inside; defects in both steps compound the problem.

Another variant within the DIO2 gene, rs12885300 (ORFa-Gly3Asp), has been studied alongside Thr92Ala in several trials. While less consistently associated with clinical outcomes, it may modulate DIO2 expression levels and has been linked to body weight changes after Graves' disease treatment¹⁹¹⁹ linked to body weight changes after Graves' disease treatment
Combined analysis shows additive effects.

Compound implication for DIO2 Thr92Ala + MCT10 rs17606253: Individuals carrying both the DIO2 C allele (CT or CC) and the MCT10 variant may experience more pronounced difficulties with T4 monotherapy and show the strongest preference for T4+T3 combination treatment. If you match this profile and have persistent hypothyroid symptoms despite normal TSH on levothyroxine, discuss combination therapy with your endocrinologist, citing the Carle et al. 2017 study.

Lipoprotein lipase (LPL) is the central enzyme that clears triglyceride-rich particles¹¹ triglyceride-rich particles
Very low-density lipoproteins (VLDL) and chylomicrons — the main carriers of dietary and liver-made fats in the bloodstream from circulation. LPL activity sets the pace for how quickly you clear fat from your blood after eating. The rs264 variant, located in intron 6 of the LPL gene (NM_000237.3:c.776-172G>A), is an intronic polymorphism with genome-wide-significant associations with circulating triglyceride and HDL cholesterol levels.

The Mechanism

As an intronic variant 172 nucleotides upstream of exon boundaries, rs264 does not directly alter the LPL protein sequence. Intronic LPL variants like rs264, the classical HindIII polymorphism (rs320, intron 8), and the PvuII polymorphism (rs285, intron 6) are thought to influence LPL expression or mRNA processing through effects on regulatory elements or splicing enhancers²² regulatory elements or splicing enhancers
Intronic sequences can contain binding sites for transcription factors, splicing regulatory proteins, and microRNAs. Changes in these elements alter how much protein is made, or whether alternative splice forms are produced. The nearby functional variant rs13702 (3′ UTR of LPL) is a well-characterised gain-of-function allele that disrupts a microRNA-410 binding site; rs264 lies in a different regulatory region and may affect expression via a distinct mechanism. Carriers of the minor A allele tend to show phenotypic patterns consistent with modestly reduced LPL activity — higher triglycerides and lower HDL cholesterol — without the severity seen in coding loss-of-function mutations.

The Evidence

The LPL locus is one of the strongest genetic determinants of circulating lipids. Teslovich et al.³³ Teslovich et al.
Teslovich NM et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 2010 identified LPL as a genome-wide-significant locus for both triglycerides and HDL-C in a meta-analysis of over 100,000 individuals. Within the LPL region, Peloso et al.⁴⁴ Peloso et al.
Peloso GM et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 adults. JAMA, 2014 confirmed rs264 as part of the LPL haplotype block associated with lower triglycerides (p=5×10⁻⁴⁶), higher HDL-C (p=7×10⁻⁴⁸), and inverse CAD risk (p=3×10⁻⁹), with the common G allele carrying the beneficial lipid-lowering direction.

Population studies have provided direct evidence for the minor A allele. Osman et al.⁵⁵ Osman et al.
Osman W et al. Genetics of type 2 diabetes and coronary artery disease and their associations with twelve cardiometabolic traits in the UAE population. PLOS ONE, 2020 found the strongest CAD association in their UAE cohort at rs264 (OR=1.96 for allele A, p=0.009) and noted that the AA genotype was enriched among patients with type 2 diabetes. A 2024 case-control study Laszlo et al.⁶⁶ Laszlo et al.
Laszlo L et al. LPL rs264, PROCR rs867186 and PDGF rs974819 gene polymorphisms in patients with unstable angina. J Pers Med, 2024 confirmed lower serum HDL levels in AA carriers compared to GA heterozygotes, though rs264 alone did not independently predict unstable angina risk in a European cohort — consistent with it being a moderate-effect modifier rather than a major causal variant.

The A allele minor frequency varies from ~13% in African populations to ~20% in East Asian populations, meaning that about 2% of people globally carry two copies (AA genotype), with the greatest burden in East Asian ancestry groups.

Practical Implications

The actionable context of rs264 centres on LPL activity optimisation. Because the A allele is associated with modestly reduced LPL-mediated clearance of triglyceride-rich particles, dietary strategies that reduce the triglyceride load entering circulation and pharmacological approaches that boost LPL activity are particularly relevant. Omega-3 fatty acids (EPA/DHA) reduce hepatic VLDL secretion and, via PPAR-α activation, upregulate LPL gene expression — making them a mechanistically targeted intervention for A-allele carriers. Limiting dietary refined carbohydrates and fructose reduces the hepatic triglyceride production that LPL must clear. Fasting lipid panels are the key monitoring tool: triglycerides and HDL-C are the direct readout of LPL functional capacity.

Interactions

The LPL gene harbours multiple functionally relevant variants that operate independently. The gain-of-function S447X variant (rs328, exon 9) generates a truncated LPL protein with paradoxically higher lipolytic activity; rs328 and rs264 may be on different haplotype backgrounds. The HindIII RFLP (rs320, intron 8) is another intronic variant with lipid associations; rs320 and rs264 are in partial LD and their combined effect is likely additive. APOA5 S19W (rs3135506) reduces LPL stimulation by apoAV and raises triglycerides independently; APOA5 + LPL variant combinations have documented additive effects on hypertriglyceridemia risk (ICARIA study, PMID 20429872). ANGPTL4 (rs116843064) inhibits LPL; a partial loss-of-function ANGPTL4 allele has additive protective effects when combined with LPL gain-of-function variants. For individuals with rs264 AA combined with other LPL/APOA5 triglyceride-raising variants, fasting triglycerides should be monitored carefully given the cumulative risk.

Every cell in your immune system carries a genetic volume knob for inducible nitric oxide synthase (iNOS), the enzyme that produces high-output bursts of nitric oxide during inflammatory responses. The rs2779249 variant sits in the NOS2 promoter region at position −1026 relative to the transcription start site — a regulatory element that controls how loudly the iNOS gene responds to inflammatory signals. Carrying the A allele at this position turns the volume up, and the functional data are clear: the A allele increases iNOS promoter transcriptional activity up to 5-fold compared to the C allele¹¹ 5-fold compared to the C allele
measured in luciferase reporter assays; the A allele alters binding of the transcription factor YY1 at this site, shifting the balance from transcriptional repression to activation.

The −1026C/A substitution sits within a transcription factor binding site in the NOS2 promoter. Functional studies using promoter-reporter constructs²² Functional studies using promoter-reporter constructs
Deng et al. Functional single nucleotide polymorphism -1026C/A of inducible nitric oxide synthase gene. Mol Cell Biochem. 2010 established that this position binds Yin Yang 1 (YY1), a transcription factor with repressor activity at this locus. The C allele supports dominant YY1 binding, which restrains NOS2 expression. The A allele disrupts YY1 occupancy and allows Nuclear Factor I (NFI) to bind preferentially — a factor that activates rather than represses transcription. The result is a constitutively more responsive NOS2 promoter: when pro-inflammatory signals arrive (NF-κB activation from infection, dietary triggers, adipokines, or cellular stress), iNOS mRNA levels rise higher and faster in A-allele carriers.

Critically, this is a transcriptional volume effect, not a protein function effect. Unlike rs2297518 (the S608L coding variant in the same gene that increases per-molecule iNOS enzymatic activity), rs2779249 controls how many iNOS molecules are made in the first place. The two variants therefore operate at different levels of the same output system — and when co-inherited, their effects on total nitric oxide production are additive.

The downstream consequences of chronically elevated iNOS output are the same regardless of which NOS2 variant drives it: excess NO reacts with superoxide (O₂⁻) to form peroxynitrite (ONOO⁻)³³ peroxynitrite (ONOO⁻)
a potent reactive nitrogen species that nitrates proteins, oxidizes lipids, and damages mitochondrial DNA — far more destructive than either NO or superoxide alone. Peroxynitrite-mediated damage accumulates as 3-nitrotyrosine (3-NT)⁴⁴ 3-nitrotyrosine (3-NT)
a stable biomarker of in vivo nitrosative stress, elevated in aging, cardiovascular disease, neurodegeneration, and metabolic syndrome, and activates NF-κB in a positive feedback loop that sustains inflammatory gene expression — a molecular description of inflammaging⁵⁵ inflammaging
the chronic, low-grade, sterile inflammation that underlies most major age-related diseases.

The most direct evidence for rs2779249's functional importance comes from the 2009 mechanistic study (PMID 19402223) that demonstrated the 5-fold promoter activity difference between alleles and identified the YY1/NFI transcription factor switch as the molecular basis. This level of functional characterization — allele-specific promoter activity measured directly in human cells — places rs2779249 among the better-characterized regulatory SNPs in the NOS2 locus.

For clinical associations, the TAMRISK study⁶⁶ TAMRISK study
Muranen L et al. Functional Inducible Nitric Oxide Synthase Gene Variants Associate With Hypertension: A Case-Control Study in a Finnish Population. Medicine (Baltimore). 2015 is the strongest dataset. Among 320 hypertensive cases and 439 normotensive controls aged 50, A-allele carriers had OR = 1.47 (95% CI 1.08–2.01, p = 0.015) for hypertension at age 50. Prospective 15-year follow-up data from prior cross-sections (ages 35, 40, 45) showed even larger effects earlier in life — at age 35, OR = 3.83 (95% CI 1.20–12.27, p = 0.024) — suggesting the promoter variant's effect on vascular risk is visible decades before clinical hypertension typically manifests. The critical haplotype finding: when rs2779249-A and rs2297518-A were co-inherited as haplotype H3 (present in ~20% of the study population), the hypertension OR rose to 2.01 (95% CI 1.29–3.12, p = 0.002), larger than either variant alone.

An independent Han Chinese replication⁷⁷ An independent Han Chinese replication
Relationship between inducible NOS single-nucleotide polymorphisms and hypertension in Han Chinese. Herz. 2017 in 1,172 hypertensive and 1,172 control subjects confirmed the association: rs2779249 A allele was associated with hypertension with OR = 1.27 (additive model), 1.31 (dominant), and 1.68 (recessive). The replication in a second major population substantially strengthens the confidence in the finding.

An Eastern Siberian cohort study⁸⁸ An Eastern Siberian cohort study
Alyabyeva et al. Association of SNPs Rs2779249 and Rs2297518 of NOS2 with tension-type headache and hypertension overlap syndrome. Genes (Basel). 2023 of 91 participants found the A allele frequency elevated from 14.5% in healthy controls to 35% in overlap syndrome patients (OR 3.17 for overlap, OR 2.94 for arterial hypertension alone), confirming the vascular signal in a further population.

Beyond vascular disease, a 2023 bladder cancer case-control study⁹⁹ a 2023 bladder cancer case-control study
Wróbel-Bednarz K et al. The role of SOD2 and NOS2 genes in bladder cancer pathophysiology. Sci Rep. 2023 found a sex-differentiated association: CA heterozygotes had reduced bladder cancer risk overall, while CC homozygotes (who lack the A allele entirely) had increased bladder cancer risk specifically in women — a paradox that may reflect tissue-specific roles of NOS2 expression in tumor immune surveillance versus nitrosative DNA damage, or differential iNOS/NO effects in tumor initiation versus progression.

Because rs2779249 increases iNOS transcriptional output, the most impactful interventions are those that reduce NF-κB-driven iNOS induction signals — the upstream triggers that the amplified promoter responds to. Every reduction in the inflammatory signals reaching the NOS2 promoter translates directly to less iNOS mRNA, fewer iNOS protein molecules, and lower peroxynitrite output. The same dietary, antioxidant, and monitoring strategies that apply to rs2297518 carriers apply here — but with the emphasis shifted toward reducing induction stimuli rather than countering enzymatic output directly.

Key modifiable inducers of NOS2 transcription include: dietary saturated fat and advanced glycation end products (AGEs) that activate NF-κB through TLR4; visceral adipose tissue cytokines (TNF-α, IL-6, IL-1β); chronic low-grade infections (periodontal, gut dysbiosis, respiratory); and sleep restriction, which activates NF-κB through hypoxia-inducible factor signaling. Each of these inputs drives NF-κB → NOS2 transcription, and in A-allele carriers, the amplified promoter magnifies the response to each trigger.

Blood pressure monitoring is the highest-yield clinical action, given the consistent hypertension signal across Finnish, Chinese, and Siberian cohorts.

rs2779249 and rs2297518 form the NOS2 haplotype H3 (both A alleles co-inherited) that is the most clinically relevant genetic unit in this locus. The TAMRISK study documented¹⁰¹⁰ The TAMRISK study documented
Muranen L et al. 2015 that H3 carries OR = 2.01 for hypertension, larger than either variant alone — consistent with the additive model in which promoter-driven increased transcription (rs2779249-A) combines with per-molecule increased enzymatic activity (rs2297518-A) to produce maximal total NO output. Carriers of both A alleles should receive the most intensive monitoring and intervention recommendations. An Italian migraine study¹¹¹¹ An Italian migraine study
Esposito M et al. Inducible nitric oxide synthase haplotype associated with migraine and aura. Mol Cell Biochem. 2012 found the same H3 haplotype more prevalent in migraine with aura (19% vs 10% in controls, p = 0.0245), adding a neurological dimension to the haplotype's effect.

The AKT1 variant rs3803304¹²¹² AKT1 variant rs3803304
intronic AKT1 variant associated with reduced longevity in centenarian studies intersects with the NOS2 promoter through a distinct mechanism: AKT1 phosphorylates and stabilizes NOS2 mRNA, increasing iNOS protein expression from a given level of mRNA. Carriers of risk alleles in both rs2779249 (increased transcription) and rs3803304 (increased mRNA stability) would theoretically experience synergistic iNOS protein elevation, though this combination has not been directly tested in human cohorts.

Your bones are constantly being broken down and rebuilt. At the heart of that process in cortical bone¹¹ cortical bone
the dense outer shell that forms 80% of the skeleton and provides most of its mechanical strength sits the WNT16 protein — a signaling molecule secreted by bone-forming cells that keeps bone-resorbing cells in check. The rs2908004 variant introduces a single amino acid change (glycine to arginine at position 82) in WNT16 that impairs this regulatory function. Carriers of the G allele at this position tend toward thinner cortical bone, lower bone mineral density at fracture-prone sites, and elevated lifetime fracture risk. Unlike the neighboring intronic variant rs3801387 that influences WNT16 expression levels, rs2908004 directly alters the WNT16 protein structure.

The Mechanism

WNT16 is expressed predominantly by osteoblasts — bone-forming cells lining cortical bone surfaces²² expressed predominantly by osteoblasts — bone-forming cells lining cortical bone surfaces. It suppresses osteoclast (bone-resorbing cell) formation through two parallel pathways: directly inhibiting osteoclast progenitor differentiation via a non-canonical Wnt pathway³³ non-canonical Wnt pathway
a signaling branch independent of the classic beta-catenin cascade, and indirectly through upregulating osteoprotegerin (OPG) — a decoy receptor for the osteoclast-activating signal RANKL. The net effect is preserved cortical thickness and reduced endocortical porosity.

The Gly82Arg substitution replaces a small, flexible glycine residue with a bulky, positively-charged arginine at position 82 in the WNT16 protein. Glycine residues at structural turning points in proteins are often critical for proper folding; their replacement frequently alters protein conformation and interaction with binding partners. Position 82 lies within the cysteine-rich domain (CRD)⁴⁴ cysteine-rich domain (CRD)
the domain responsible for binding to WNT receptors (Frizzled family) and co-receptors; essential for signal transduction, the functional core of WNT ligands. Disrupting CRD geometry is a well-documented mechanism by which WNT family missense variants reduce signaling activity, consistent with the observed association between the G allele and lower BMD.

The Evidence

The definitive evidence for rs2908004 comes from a landmark GWAS meta-analysis by Zheng et al. (2012)⁵⁵ landmark GWAS meta-analysis by Zheng et al. (2012) spanning 5,878 European subjects across multiple cohorts. The G allele at rs2908004 was associated with a −0.16 SD reduction in forearm BMD per allele (P = 1.2×10⁻¹⁵ — far exceeding genome-wide significance thresholds). Forearm BMD reflects cortical bone at the distal radius, one of the most common fragility fracture sites. The same study found a forearm fracture OR of 1.22 per G allele (P = 4.9×10⁻⁶).

García-Ibarbia et al. (2013)⁶⁶ García-Ibarbia et al. (2013) studied 1,083 Spanish individuals and found rs2908004 associated with femoral neck BMD (average difference 35 mg/cm²; p = 0.00037), calcaneal ultrasound parameters (p = 0.00004), and femoral neck buckling ratio (p = 0.0007) — a geometric measure of fracture susceptibility. Among individuals under 80 years old, protective genotypes were significantly underrepresented in hip fracture patients (OR 0.50 for the protective genotype).

Age of study matters: Correa-Rodríguez et al. (2016)⁷⁷ Correa-Rodríguez et al. (2016) demonstrated that rs2908004 influences broadband ultrasound attenuation (BUA)⁸⁸ broadband ultrasound attenuation (BUA)
a quantitative ultrasound parameter that measures bone density and microarchitecture at the heel without radiation exposure even in young adults (mean age 20, n=575; p = 0.001). This positions the variant as a determinant of peak bone mass acquisition, not just age-related bone loss — making early intervention particularly meaningful.

The largest population study, the Taiwan Biobank analysis (Wu et al. 2022)⁹⁹ Taiwan Biobank analysis (Wu et al. 2022) with 10,942 participants, confirmed a 35% lower osteoporosis risk in those with GA or AA genotypes compared to GG (OR 0.651; 95% CI 0.544–0.780). Importantly, the interaction between rs2908004 genotype and BMI was statistically significant (p = 0.0148), with underweight GG individuals facing particularly elevated risk (OR 7.66 vs normal-weight GG).

Practical Actions

The consistent finding across European and East Asian populations is that the G allele impairs WNT16-mediated osteoclast suppression, translating to thinner cortical bone and higher fracture risk at the wrist, hip, and other cortical-dominant sites. The effect operates additively: two copies of G confer the most risk, one copy intermediate risk, and AA (no G) offers the best genetic protection.

For GG individuals, building and protecting cortical bone requires active intervention. The two most evidence-backed strategies are ensuring adequate calcium (1,000–1,200 mg/day) and vitamin D (supporting levels of 30–60 ng/mL), combined with mechanical loading via weight-bearing exercise, which stimulates periosteal bone apposition — the cortical-specific growth mechanism most relevant to WNT16 function. For those under 30, the priority is maximizing peak bone mass; for those older, minimizing cortical bone loss rate.

The interaction with underweight status (BMI interaction p = 0.0148) is clinically meaningful: GG individuals who are underweight face compounded risk. Low body weight accelerates cortical bone loss through reduced mechanical load and lower estrogen/androgen levels — exactly the pathways WNT16 impairment already compromises.

Interactions

Rs2908004 is in high linkage disequilibrium with rs3801387 (intronic, regulatory) and rs2707466 (another missense variant, Thr>Ile), which together form a WNT16 haplotype block spanning 7q31.31¹⁰¹⁰ WNT16 haplotype block spanning 7q31.31. These variants partially tag each other, but rs2908004 captures the coding-level impact directly. The Zheng 2012 analysis showed both missense variants contributing to the cortical bone signal, with rs2707466 showing the stronger cortical thickness association and rs2908004 stronger for forearm BMD.

WNT16 function intersects with the broader WNT signaling architecture including LRP5 (co-receptor) and SOST (sclerostin — a WNT inhibitor). Individuals with risk variants in both WNT16 and LRP5 may face compounded cortical bone deficits. Separately, the BMI interaction (Wu et al. 2022) suggests WNT16 genotype modifies how body composition affects bone health — providing a precision lens on dietary and exercise counseling that goes beyond standard advice.

The heart beats more than 2.5 billion times over a lifetime. Sustaining that rhythm requires adhesion structures strong enough to withstand constant mechanical stress — and the primary load-bearing junction between adjacent cardiac muscle cells is the desmosome¹¹ desmosome
protein complex that acts as a molecular rivet at sites of peak tension in cardiomyocytes. Desmoplakin (DSP) is the central structural element of the desmosome, linking the desmosomal plaque to the intermediate filament cytoskeleton inside the cell. The Trp550Ter variant — a G-to-A substitution at chromosome 6 position 7,570,512 — converts codon 550 from tryptophan to a stop signal, truncating the protein at less than 19% of its full 2,872-amino-acid length and eliminating its entire functional architecture.

The Mechanism

The c.1650G>A substitution converts the tryptophan codon (TGG) to a stop codon (TGA) at position 550, near the start of desmoplakin's central plakin domain. The resulting truncated transcript is expected to undergo nonsense-mediated mRNA decay²² nonsense-mediated mRNA decay
a cellular surveillance pathway that degrades mRNAs containing premature stop codons, preventing production of potentially toxic truncated proteins, eliminating functional desmoplakin from the affected allele. The consequence is haploinsufficiency — roughly half the normal DSP output from a single intact copy. With codon 550 in the N-terminal region, this truncation is particularly severe: the entire plakin domain, both spectrin repeats, and the C-terminal intermediate-filament-binding domain are lost. Desmosomal junctions with only half the normal desmoplakin cannot maintain adhesion under the cyclic mechanical load of cardiac contraction. Cells detach; the heart patches the torn junctions with scar tissue; the resulting fibrosis creates a pro-arrhythmic substrate.

DSP-related arrhythmogenic cardiomyopathy (DSP-ACM) is clinically distinct from the classical right-dominant arrhythmogenic right ventricular cardiomyopathy (ARVC). In a landmark series of 107 DSP-mutation patients, 55% showed exclusively left ventricular involvement versus 0% of PKP2-mutation carriers³³ 55% showed exclusively left ventricular involvement versus 0% of PKP2-mutation carriers. Episodic myocarditis-like events — chest pain, troponin elevation, and cardiac MRI changes indistinguishable from acute myocarditis — occur in 14–22% of carriers, often as the first clinical presentation, and significantly accelerate downstream fibrosis and arrhythmia risk.

The Evidence

Three large studies define the clinical burden of DSP pathogenic variants. Gasperetti et al. (European Heart Journal, 2025)⁴⁴ Gasperetti et al. (European Heart Journal, 2025) followed 800 DSP variant carriers across 26 institutions and documented sustained ventricular arrhythmia in 17.4% (3.9% per year). A striking 32.5% of carriers did not meet established diagnostic criteria for any cardiomyopathy subtype, illustrating how easily DSP-ACM escapes standard workup. Myocardial injury episodes increased ventricular arrhythmia risk 2.4-fold and heart failure hospitalizations 5.1-fold.

Hoorntje et al. (Circ Genomic Precis Med, 2023)⁵⁵ Hoorntje et al. (Circ Genomic Precis Med, 2023) demonstrated that among 170 individuals with DSP truncating variants, 33% experienced major ventricular arrhythmia. Crucially, variants in positions expected to trigger nonsense-mediated decay — which the Trp550Ter variant almost certainly does, given its N-terminal location — were independently associated with higher arrhythmic risk compared with truncating variants that escape decay. The earlier the stop codon, the less likely a stable partial protein escapes.

Jacobsen et al. (Heart Rhythm, 2025)⁶⁶ Jacobsen et al. (Heart Rhythm, 2025) showed that among 100 DSP variant carriers, those engaging in high-level endurance activity had a 2.37-fold increased risk of myocardial injury episodes; each such episode predicted subsequent arrhythmia with a hazard ratio of 7.86 and heart failure with a hazard ratio of 10.28. Vigorous endurance sports are an environmental modifier that accelerates disease expression.

Practical Actions

Heterozygous carriers require cardiac surveillance even without symptoms. Baseline evaluation includes cardiac MRI with late gadolinium enhancement (the primary tool for detecting early LV fibrosis before ejection fraction falls), 24–48-hour Holter monitoring for PVC burden and non-sustained VT, and a resting ECG. Specialists typically recommend annual to biennial surveillance thereafter, with accelerated imaging after any episode of chest pain or troponin elevation. High-intensity competitive sport should be assessed individually with a cardiologist before continuing. First-degree relatives carry a 50% probability of inheriting the variant and should undergo cascade genetic testing.

Interactions

DSP-ACM risk is amplified by additional desmosomal gene variants. Carrying pathogenic variants in two desmosomal genes simultaneously — compound digenic inheritance — is associated with earlier onset and more severe phenotype. Relatives carrying both this DSP variant and a pathogenic variant in PKP2 (rs111517471) or DSG2 warrant particularly intensive surveillance. Physical activity level is the most important environmental modifier: endurance athletes with desmosomal variants develop cardiomyopathy at substantially higher rates and earlier ages than sedentary carriers, a finding now reflected in cardiology society guidance discouraging competitive sport pending formal evaluation.

APOE¹¹ Apolipoprotein E is a protein that helps transport cholesterol and other fats through the bloodstream is one of the most important genes in human genetics. It affects cholesterol transport, brain health, and longevity. Your APOE genotype is determined by two variants: rs429358 (this one, the E4 determinant) and rs7412 (the E2 determinant).

The Mechanism

The rs429358 variant causes a missense change at position 130 of the APOE protein, substituting cysteine with arginine (p.Cys130Arg). This single amino acid change defines the APOE ε4 isoform, which has reduced ability to clear LDL cholesterol from the bloodstream and impaired amyloid-beta clearance in the brain.

APOE Genotypes

The combination of rs429358 and rs7412 gives you one of six APOE genotypes: ε2/ε2, ε2/ε3, ε3/ε3, ε3/ε4, ε2/ε4, or ε4/ε4. ε3/ε3 is the most common (about 60% of people). The ε4 allele frequency varies dramatically across populations — from ~7% in South Asians to ~27% in sub-Saharan Africans.

The Evidence

The landmark study by Corder et al.²² landmark study by Corder et al.
Corder et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 1993 showed that each ε4 allele increases Alzheimer's risk and lowers age at onset. Risk increased from 20% to 90% with increasing ε4 dose.

A major meta-analysis³³ major meta-analysis
Farrer et al. Effects of age, sex, and ethnicity on the association between APOE genotype and Alzheimer disease. JAMA, 1997 of 5,930 AD patients and 8,607 controls confirmed that one ε4 copy roughly triples risk (OR ~3.2 for ε3/ε4) and two copies raise it about 15-fold (OR ~14.9 for ε4/ε4). The effect is strongest in Caucasians and Japanese, weaker in African Americans and Hispanics.

E4 and Saturated Fat

APOE E4 carriers have a stronger negative response to dietary saturated fat. Their LDL cholesterol rises more sharply with saturated fat intake compared to non-carriers. This makes dietary fat choices particularly important for E4 carriers.

E4 and Alzheimer's

Each E4 allele increases Alzheimer's risk⁴⁴ One E4 copy roughly triples risk; two copies raise it roughly 12-15-fold, though absolute risk still depends on many other factors including age, sex, and lifestyle, but it's not deterministic. Lifestyle factors — exercise, diet, sleep, cognitive engagement — can significantly modify this risk.

Interactions

APOE E4 risk compounds with TCF7L2 (rs7903146) — if you carry risk alleles at both, limiting dietary fat is especially important. The rs429358 and rs7412 variants together determine your complete APOE genotype.

Vitamin B6 is not a single molecule but a family of related compounds — pyridoxine, pyridoxal, pyridoxamine, and their phosphorylated forms — that your body continuously interconverts. The active coenzyme form is pyridoxal 5'-phosphate (PLP)¹¹ pyridoxal 5'-phosphate (PLP)
The phosphorylated, active form of vitamin B6 that acts as a coenzyme in over 100 enzymatic reactions, which participates in over 100 enzymatic reactions, from amino acid metabolism and neurotransmitter synthesis to homocysteine clearance and immune function. Despite its importance, circulating PLP levels vary substantially between people eating identical diets. A significant portion of that variation is genetic. The rs4654748 variant, located in an intron of the NBPF3 gene on chromosome 1 and in tight linkage disequilibrium with the nearby ALPL²² ALPL
Alkaline phosphatase, liver type — a cell-surface enzyme that hydrolyzes phosphorylated substrates including PLP, controlling how much circulating B6 is available to tissues gene, is the single strongest common genetic predictor of circulating PLP levels identified by genome-wide association studies. It does not break a gene — it fine-tunes an enzyme that degrades B6, shifting your steady-state PLP level up or down depending on how many C alleles you carry.

The Mechanism

Tissue-nonspecific alkaline phosphatase (TNSALP), encoded by ALPL, is a cell-surface enzyme expressed in liver, bone, kidney, and intestine. One of its natural substrates is circulating PLP: TNSALP dephosphorylates PLP to pyridoxal, which crosses cell membranes more easily, then cells rephosphorylate it back to PLP for use as a coenzyme. This cycle effectively controls how much PLP remains in circulation at any given time. The C allele at rs4654748 is associated with a more active or more highly expressed form of the enzyme at this locus. When alkaline phosphatase activity was included in regression models³³ When alkaline phosphatase activity was included in regression models
Tanaka T et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine. Am J Hum Genet, 2009, the association of rs4654748 with plasma B6 disappeared — confirming that ALP activity is the mediating mechanism. C allele carriers have faster PLP catabolism, leading to lower steady-state circulating PLP, even with identical dietary B6 intake.

The Evidence

The founding study by Tanaka et al. 2009⁴⁴ Tanaka et al. 2009
Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet, 2009 conducted a genome-wide association analysis in three Italian cohorts (InCHIANTI, SardiNIA, BLSA; N = 2,930), identifying rs4654748 as the top locus (p = 1.21 × 10⁻⁸), with replication in an independent cohort of 687 participants (p = 2.08 × 10⁻¹¹). The meta-analysis yielded p = 8.3 × 10⁻¹⁸ and an effect of 1.45 ng/mL lower vitamin B6 per copy of the C allele — an additive, dose-dependent effect. A subsequent meta-analysis of 4,763 participants across three genome-wide scans⁵⁵ 4,763 participants across three genome-wide scans
Hazra A et al. Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway. Hum Mol Genet, 2009 confirmed the chromosome 1p36 locus association with plasma PLP (p = 1.40 × 10⁻¹⁵ for the locus), placing it among the most robustly replicated nutrition-metabolism GWAS findings. A candidate gene study in 2,345 healthy Irish adults⁶⁶ candidate gene study in 2,345 healthy Irish adults
Carter TC et al. Common variants at putative regulatory sites of ALPL influence circulating PLP. J Nutr, 2015 identified 17 ALPL SNPs associated with plasma PLP at genome-wide significance, with rs4654748 (MAF 0.48) among the top hits (p = 4.61 × 10⁻⁸). The locus also influences B6 vitamer ratios in cerebrospinal fluid⁷⁷ B6 vitamer ratios in cerebrospinal fluid
Loohuis LM et al. The alkaline phosphatase (ALPL) locus is associated with B6 vitamer levels in CSF and plasma. Genes, 2018, not just plasma, confirming that peripheral B6 metabolism affects the brain's B6 supply and making the locus relevant to neurological as well as metabolic outcomes.

Practical Actions

People with the CC genotype have chronically lower circulating PLP than TT individuals on equivalent diets, by approximately 2.9 ng/mL. This gap widens when dietary B6 intake is marginal. The typical plasma PLP reference range is roughly 20–100 nmol/L (5–25 ng/mL), so a 2.9 ng/mL reduction represents a meaningful downward shift, particularly for people near the lower end of normal. The most direct countermeasure is supplementing with pyridoxal-5-phosphate (P5P)⁸⁸ pyridoxal-5-phosphate (P5P)
The already-active coenzyme form of B6 that does not require hepatic conversion and is taken up directly by tissues. Unlike pyridoxine (the synthetic form found in most multivitamins), P5P does not need to be converted by the liver and is not subject to competitive inhibition with active B6 at high doses. For CC carriers with documented low plasma PLP, P5P (10–25 mg/day) provides the active form directly, bypassing the catabolism bottleneck at ALPL. Dietary B6 remains important: animal proteins (poultry, fish, beef liver), chickpeas, bananas, and fortified cereals are the richest sources. However, given that the variant affects catabolism rather than absorption, dietary intake targets for CC carriers should be at the upper end of the RDA range (1.7 mg/day for adults over 50; 1.3 mg/day for younger adults), with consideration of supplementation if plasma PLP is confirmed low. Plasma PLP can be measured directly — either as part of a vitamin B6 profile panel or as a standalone test. This is the most useful monitoring option for CC carriers, particularly given B6's role in homocysteine transsulfuration and neurotransmitter synthesis.

Interactions

Vitamin B6 (PLP) is a required cofactor for cystathionine beta-synthase and cystathionine gamma-lyase⁹⁹ cystathionine beta-synthase and cystathionine gamma-lyase
The two enzymes of the transsulfuration pathway that convert homocysteine to cysteine and glutathione, the transulfuration enzymes that convert homocysteine to cysteine. Chronically lower PLP in CC carriers may reduce the efficiency of homocysteine clearance through this pathway, particularly when the folate-dependent remethylation route (which requires MTHFR) is also impaired. This creates a potential compound interaction with MTHFR C677T (rs1801133) and MTRR A66G (rs1801394): when folate-mediated remethylation is reduced and B6-dependent transsulfuration is also less efficient, homocysteine can accumulate significantly. Individuals carrying CC at rs4654748 together with the homozygous risk genotype at MTHFR C677T (rs1801133) may benefit from supplementation addressing both the B6 and methylfolate pathways simultaneously. This compound interaction is worth monitoring with a serum homocysteine test. PLP is also a cofactor for SHMT1 (rs1979277), the enzyme converting serine to glycine in the folate cycle. Reduced PLP in CC carriers may compound SHMT1 variants that already impair this step.

Your immune system detects bacterial invaders through a set of sentinel proteins called Toll-like receptors. TLR1 acts as a co-detector for triacylated lipopeptides — the fatty-acid decorated proteins that coat many gram-positive bacteria, mycobacteria, and fungi. It does this not alone, but as an obligate heterodimer with TLR2: TLR1 grasps one of the three lipid chains of the pathogen while TLR2 anchors the complex. The N248S variant sits directly in this extracellular recognition domain, and the serine substitution impairs how efficiently the receptor captures its ligand.

This is the second functional missense variant in TLR1 in the GeneOps database — the other being I602S (rs5743618), which disrupts intracellular trafficking. Whereas I602S prevents TLR1 from ever reaching the cell surface, N248S alters the protein that does reach the surface, weakening the initial contact between receptor and bacterial lipopeptide.

The Mechanism

TLR1's extracellular domain contains a series of leucine-rich repeat (LRR) modules arranged in a horseshoe shape. In the crystal structure of the TLR1-TLR2 heterodimer¹¹ crystal structure of the TLR1-TLR2 heterodimer
Jin et al., 2007; resolved to 2.1 Å showing lipopeptide lodged in a hydrophobic channel in TLR1's LRR domain, position 248 falls within the central LRR region that forms part of the heterodimerization interface between TLR1 and TLR2.

Asparagine at position 248 carries a polar amide side chain capable of hydrogen bonding. The serine substitution (N248S) replaces this with a shorter hydroxyl group, altering the local surface geometry at a region implicated in receptor-receptor contact. Studies of functional outcomes show that this change diminishes TLR1/TLR2 signaling to triacylated lipopeptide stimulation in cellular assays — reduced NF-κB activation and attenuated cytokine production. This includes documented loss-of-function in HMGB1-mediated TLR1–TLR2 signaling²² HMGB1-mediated TLR1–TLR2 signaling
HMGB1 is a damage-associated molecular pattern that activates TLR1/TLR2 as a secondary pathway alongside its RAGE and TLR4 interactions.

Because N248S and I602S (rs5743618) are in linkage disequilibrium — they co-segregate on the same haplotype in most populations — individuals carrying one variant often carry both. The extracellular impairment of N248S and the trafficking impairment of I602S therefore tend to compound on the same chromosome.

The Evidence

Leprosy and mycobacterial disease: Schuring et al. (2009)³³ Schuring et al. (2009)
Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions. J Infect Dis 199:1816–9 genotyped rs4833095 in a Bangladeshi leprosy cohort and found that the SS homozygous genotype (Ser/Ser, CC on plus strand) was significantly over-represented in leprosy patients vs controls (p=0.012). Heterozygous NS carriers were under-represented (p=0.015), a protective heterozygote effect also seen in I602S data⁴⁴ I602S data. The mechanism is consistent with reduced TLR1 signaling failing to generate the robust mycobacterial response needed for early pathogen control — though the same blunted response can reduce immunopathology in chronic infection.

A sex-stratified Brazilian study by Brito-de-Souza et al. (2018)⁵⁵ Brito-de-Souza et al. (2018)
The TLR1 gene is associated with higher protection from leprosy in women. PLOS One found that the heterozygous C/T genotype was protective specifically in women (OR=0.54, 95% CI 0.32–0.91, p=0.02) but not in men. This sex-specific finding suggests that sex hormones modulate TLR1-dependent immunity, with women gaining a signal-buffering benefit from heterozygosity.

Gram-positive sepsis mortality: In a traumatic-injury cohort study, Wurfel et al.⁶⁶ Wurfel et al.
Toll-like Receptor 1 Polymorphisms and Associated Outcomes in Sepsis Following Traumatic Injury. PMC3686843 found that the Ser248 allele (C on plus strand; G in the coding-strand notation used in that paper) was associated with OR 4.16 (95% CI 1.22–14.19, p=0.023) for in-hospital death from gram-positive sepsis, with 26.3% mortality in GG homozygotes vs 11.3% in AA homozygotes. This large effect size suggests that impaired TLR1 recognition of gram-positive bacterial lipopeptides meaningfully reduces the ability to clear these pathogens when sepsis develops.

Cytokine effects: Dos Santos et al. (2017)⁷⁷ Dos Santos et al. (2017)
Polymorphisms in TLR1, 2 and 4 associated with differential cytokine and chemokine serum production in leprosy patients. PMC5354609 showed that T allele (Asn248) carriers produced significantly higher IL-12p40 and IL-17 compared to CC (Ser/Ser) homozygotes, while MCP-1 was lower in TT homozygotes. This supports the interpretation that Asn248 (T allele) enables more robust Th1 inflammatory signaling, while Ser248 (C allele) blunts it.

IgA nephropathy: In a Chinese Han population, Zhao et al. (2016)⁸⁸ Zhao et al. (2016)
TLR1 polymorphism rs4833095 as a risk factor for IgA nephropathy. PubMed 27806314 found that the T allele (Asn248, full-function form) increased IgA nephropathy risk (OR=1.27, p=0.04). This is the inverse of the infection finding: higher TLR1 activity from Asn248 may drive the excessive mucosal immune activation underlying IgA immune complex deposition in the kidney.

Prostate cancer: A TLR10-TLR1-TLR6 cluster haplotype including rs4833095 was associated with OR 0.55 (95% CI 0.33–0.90) reduced prostate cancer risk in a large US case-control study (1,414 cases, 1,414 controls), though the independent contribution of rs4833095 vs co-inherited variants in this cluster is not resolved.

Practical Implications

The clinical meaning of N248S is shaped by LD with I602S (rs5743618). Individuals who carry the C allele at both variants have additive reductions in TLR1 surface signaling: both the receptor that reaches the surface (N248S impairment) and the total amount of surface receptor (I602S trafficking impairment) are reduced. For most people in low-infection-burden environments, this blunted TLR1 response is largely asymptomatic — the immune system compensates via TLR2/TLR6 (diacylated lipopeptides), TLR4 (LPS), and TLR9 (bacterial DNA).

The actionable context is for individuals with meaningful exposure to gram-positive bacteria or mycobacteria: CC homozygotes have documented vulnerability to worse outcomes in gram-positive sepsis and leprosy-endemic settings. Early antibiotic treatment and infection prevention are the relevant levers.

For TT homozygotes (Asn248/Asn248), the intact TLR1 extracellular domain provides robust bacterial recognition — but the trade-off observed in IgA nephropathy data suggests that excessive TLR1 signaling at mucosal surfaces may contribute to aberrant immune activation in contexts where immune complex deposition matters.

Interactions

N248S is in strong LD with I602S (rs5743618) — both are functional TLR1 missense variants on the same haplotype. Most studies cannot fully disentangle their independent effects. The combined haplotype carrying both Ser248 and Ser602 produces TLR1 with both a weakened extracellular ligand-binding domain and absent cell surface trafficking.

TLR2 (rs5743708) is TLR1's obligate heterodimer partner — variants that reduce TLR2 surface expression would compound N248S impairment. TLR6 (rs5743810) handles the diacylated lipopeptide arm of TLR2-dependent signaling; its function is independent of TLR1 N248S. TLR4 (rs4986790) handles LPS from gram-negative bacteria via a separate receptor complex.

The ABO gene on chromosome 9 encodes glycosyltransferase enzymes that attach A or B sugar antigens to the surface of red blood cells and to plasma proteins including von Willebrand factor (VWF)¹¹ von Willebrand factor (VWF)
The primary bridge protein that links platelets to damaged vessel walls and carries Factor VIII in the bloodstream. rs505922 is a well-validated tag SNP sitting in the first intron of ABO; its T allele is in near-perfect linkage disequilibrium with the deletion allele that produces blood group O, while the C allele tags non-O types (A, B, and AB). This makes rs505922 one of the most informative proxies for blood group status available on consumer genotyping arrays. The ABO locus has emerged as the single strongest common genetic determinant of venous thromboembolism²² single strongest common genetic determinant of venous thromboembolism
ABO locus accounts for roughly 30% of the genetic variance in plasma VWF levels and is the most replicated genetic signal in VTE GWAS in the genome.

The Mechanism

Blood group A and B glycosyltransferases add carbohydrate chains to VWF and Factor VIII (FVIII) that slow their clearance from the bloodstream. In group O individuals, the non-functional transferase produces VWF with a shorter plasma half-life³³ shorter plasma half-life
Half-life of 10.0 hours in group O vs 25.5 hours in non-O individuals, explaining the chronically lower VWF levels in O carriers. The practical result: plasma VWF is approximately 25% higher in people with A, B, or AB blood types compared to O, and FVIII tracks VWF closely. Because VWF mediates platelet adhesion at sites of vessel injury and stabilizes FVIII — the key amplifier of the clotting cascade — non-O individuals operate with a persistently more pro-coagulant baseline.

ABO antigens are also expressed on selectins and other endothelial adhesion molecules⁴⁴ selectins and other endothelial adhesion molecules
P-selectin and E-selectin carry ABO antigens; GWAS has identified the ABO locus as the top hit for circulating levels of soluble E-selectin, contributing to a low-grade inflammatory tone in non-O individuals that further promotes plaque formation and arterial thrombosis independent of the VWF/FVIII pathway.

The Evidence

The VTE association is one of the most thoroughly replicated findings in cardiovascular genetics. A meta-analysis of 8 prospective and case-control studies⁵⁵ meta-analysis of 8 prospective and case-control studies
Approximately 30,000 combined participants across European cohorts found a pooled odds ratio of 2.09 (95% CI 1.83–2.38) for VTE in non-O vs O individuals, designating non-O blood group as the most common heritable thrombosis risk factor — more prevalent than Factor V Leiden. When Factor V Leiden is also present, the risks multiply: non-O + Factor V Leiden carriers face a ~23-fold higher VTE risk⁶⁶ non-O + Factor V Leiden carriers face a ~23-fold higher VTE risk
Compared to OO genotype without FVL, far exceeding the ~4.6-fold from FVL alone or ~1.7-fold from non-O alone.

For coronary artery disease, two large prospective cohorts — the Nurses' Health Study and Health Professionals Follow-up Study totaling 89,501 participants — found non-O blood type associated with HR 1.10 (95% CI 1.03–1.18) for incident CHD⁷⁷ non-O blood type associated with HR 1.10 (95% CI 1.03–1.18) for incident CHD
Multivariate-adjusted, accounting for conventional risk factors including blood pressure, cholesterol, smoking, and diabetes. A subsequent meta-analysis of 10 studies (174,945 participants)⁸⁸ meta-analysis of 10 studies (174,945 participants)
Including multiple independent European and Asian cohorts confirmed: non-O OR 1.14 for coronary artery disease and OR 1.16 for acute MI. For stroke, a mega-meta-analysis encompassing 145,499 ischemic stroke cases and over 2 million controls⁹⁹ mega-meta-analysis encompassing 145,499 ischemic stroke cases and over 2 million controls
Largest pooled dataset in the literature to date reported non-O OR 1.13 for ischemic stroke and OR 1.24 for type AB specifically. Across all arterial and venous endpoints, the effect size is modest but remarkably consistent across populations, study designs, and decades of research.

Practical Actions

The elevated baseline clotting tendency from non-O blood type becomes clinically relevant in situations where additional thrombosis risk is layered on top of it. Hormonal contraception (combined oral contraceptives) and hormone replacement therapy raise VTE risk 3–4 fold on their own; in non-O women, this compounds further. Non-O blood type is classified as a haemostatic abnormality equivalent to mild thrombophilia¹⁰¹⁰ Non-O blood type is classified as a haemostatic abnormality equivalent to mild thrombophilia
European guidelines recommend considering ABO blood group when counselling women about hormonal contraceptive choice alongside other thrombophilic risk factors. Progestin-only contraceptive options carry substantially lower VTE risk and are worth discussing with a clinician.

Prolonged immobilisation — long-haul flights (>4 hours), post-surgical bed rest, cast immobilisation — represents the most actionable modifiable exposure. In people with non-O blood type, compression stockings reduce travel-related asymptomatic DVT by up to 18-fold in high-risk individuals¹¹¹¹ compression stockings reduce travel-related asymptomatic DVT by up to 18-fold in high-risk individuals
Randomised data from the LONFLIT studies; NNT 37 for high-risk travellers and should be used consistently on flights over 4 hours.

Monitoring VWF antigen and activity levels can help quantify the individual haemostatic burden, particularly before elective surgery or procedures, and gives clinicians a baseline against which to assess change over time.

Interactions

The interaction with Factor V Leiden (rs6025 in the F5 gene) is the most clinically significant gene-gene interaction documented in thrombosis genetics. Carrying both non-O blood type and Factor V Leiden multiplies VTE risk to roughly 23-fold above baseline — far greater than either factor alone (1.7x and 4.6x respectively). Similarly, combination with the prothrombin G20210A variant (rs1799963) amplifies risk substantially above either variant alone.

The ABO locus is also associated with elevated circulating levels of soluble P-selectin and E-selectin, two adhesion molecules that also rise with inflammatory states. Individuals carrying rs1800629 (TNF-alpha promoter variant) or rs1205 (CRP) in addition to non-O blood type may have compounded pro-inflammatory and pro-thrombotic physiology, though combined GWAS evidence for specific compound effects remains preliminary.

The 15q25.1 chromosomal region harbors two genetically independent signals for nicotine dependence and heavy smoking. The first — rs16969968 in CHRNA5 — encodes a receptor that blunts aversive responses to nicotine, lowering the natural ceiling on how much a person smokes. The second, rs578776, tells a different neurobiological story: located in the 3' untranslated region of CHRNA3¹¹ located in the 3' untranslated region of CHRNA3
The 3' UTR is a post-transcriptional regulatory zone that controls mRNA stability, translation efficiency, and tissue-specific expression through microRNA binding sites and RNA-binding protein interactions, this variant appears to reshape how the reward system responds not to nicotine itself, but to everything else — the natural pleasures of daily life.

The two loci are in low linkage disequilibrium (r² ≈ 0.15), meaning they are inherited independently and a person can carry risk variants at one, both, or neither. This matters clinically: someone carrying GG at rs578776 and GG at rs16969968 simultaneously faces compounded biological barriers to cessation — blunted aversion to heavy smoking plus blunted motivation from non-tobacco rewards.

The Mechanism

Unlike the CHRNA5 Asp398Asn missense variant, which demonstrably reduces receptor calcium influx by ~50%, rs578776's mechanism remains under investigation²² rs578776's mechanism remains under investigation
The 3' UTR location suggests post-transcriptional regulation of CHRNA3 expression — potentially through microRNA binding affinity — but no specific miRNA target site disruption has been confirmed for this exact variant. The variant falls in the 3' UTR of CHRNA3, which encodes the alpha-3 nicotinic acetylcholine receptor subunit. The alpha-3 subunit assembles with beta-2, beta-4, and alpha-5 subunits in the medial habenula and interpeduncular nucleus — structures that regulate both aversive responses to nicotine and tonic dopaminergic signaling to the nucleus accumbens.

The functional readout most convincingly linked to rs578776 is the intrinsic reward sensitivity (IRS) endophenotype³³ intrinsic reward sensitivity (IRS) endophenotype
Measured using the late positive potential (LPP) event-related potential component, which indexes the brain's motivational attention to emotionally significant stimuli at 400–700 ms post-stimulus onset. Smokers who are homozygous for the G allele (plus-strand; C on the coding strand) are dramatically more likely to show the IRS− profile: blunted late positive potential responses to pleasant pictures (food, nature, social scenes) combined with heightened neural reactivity to cigarette-related images. The working model is that sustained nicotinic signaling through CHRNA3-containing receptors gradually recalibrates the dopamine system, narrowing incentive salience toward drug cues and away from natural rewards.

The Evidence

Bierut et al. 2008⁴⁴ Bierut et al. 2008
A family-based GWAS of habitual smoking (≥20 cigarettes/day for ≥6 months) versus light smoking (≤10 cigarettes/day) using the FBAT method identified rs578776 as a second independent locus within the 15q25.1 cluster (p=0.009). The key finding was that rs578776 and rs16969968 have r² < 0.15, establishing statistical independence. The Tobacco and Genetics Consortium subsequently confirmed genome-wide significant association with cigarettes per day⁵⁵ genome-wide significant association with cigarettes per day
The TAG consortium meta-analysis pooled data across multiple European cohorts to reach the p < 5×10⁻⁸ threshold for genome-wide significance.

The most mechanistically informative study was published in Frontiers in Psychiatry in 2013. Versace et al. measured the intrinsic reward sensitivity endophenotype⁶⁶ Versace et al. measured the intrinsic reward sensitivity endophenotype
IRS was classified using LPP amplitude to pleasant pictures vs. cigarette pictures in 104 European-ancestry smokers enrolled in a smoking cessation trial in 104 European-ancestry smokers. The rs578776 G allele (coding-strand C) conferred dramatically higher odds of IRS− membership: carriers of two protective A alleles had an odds ratio of 0.17 (95% CI: 0.07–0.46, p=0.0002) for belonging to the IRS− group — equivalent to approximately 83% lower odds of the reward deficit phenotype.

Critically, the IRS− phenotype itself predicted cessation failure across multiple timepoints: OR=2.73 at 10 weeks, OR=3.06 at 3 months, and OR=4.03 at 6 months post-quit. The SNP genotype alone did not directly predict abstinence (sample too small for individual-SNP power), but through the IRS− intermediate phenotype it indexes a biology that substantially undermines cessation. Notably, standard questionnaire measures — nicotine dependence scales, depression inventories, trait affect — were not associated with rs578776 genotype, suggesting this ERP-based endophenotype captures something qualitatively different from self-reported craving or mood.

Practical Implications

The GG genotype does not cause nicotine dependence in isolation — it describes a particular neurobiological terrain that makes dependence harder to treat once it develops. For never-smokers, awareness of elevated dependence susceptibility is the primary value. For current smokers, understanding the IRS− phenotype reframes cessation strategy: the challenge is not just managing withdrawal but restoring motivation from non-tobacco sources that the dependent brain has learned to undervalue.

Standard cessation aids address nicotine receptor activity and withdrawal; fewer directly target the reward system's blunted response to natural stimuli. Behavioral activation — systematically scheduling engagement with non-drug rewarding activities — is the cessation component most directly matched to the IRS− phenotype. This approach, embedded in cognitive-behavioral therapy for mood disorders, has been adapted for smoking cessation in programs like BSCT (Behavioral Smoking Cessation Treatment) specifically for smokers with anhedonic features.

Varenicline is notable in this context because it acts as a partial agonist at alpha-4/beta-2 receptors, reducing the contrast between smoking and not smoking by maintaining baseline nicotinic tone during cessation — potentially bridging the reward gap while natural reward sensitivity recovers.

Interactions

rs578776 (CHRNA3 3' UTR, Locus 2) is in low LD with all three other 15q25.1 variants already in the GeneOps database: rs1051730 (CHRNA3 Tyr215Tyr, r²≈0.15), rs16969968 (CHRNA5 Asp398Asn, r²<0.15), and rs2036527 (CHRNA5 enhancer, partial LD). A person inheriting risk alleles at rs578776 and rs16969968 simultaneously faces compounded barriers: reduced nicotinic aversion to heavy smoking (CHRNA5 mechanism) and blunted natural reward sensitivity (CHRNA3 Locus 2 mechanism).

Population frequencies at rs578776 differ substantially from the other 15q25.1 variants. In East Asians, the G risk allele is rare (18% frequency) while the protective A allele dominates (82%), a near-inversion of the European pattern (G=72%). This population divergence supports the hypothesis that rs578776 tags a functional variant under distinct evolutionary pressure in different ancestries, separate from the evolutionary forces shaping rs16969968.